Bb Biotech Ag Raised Esperion Therapeutics (ESPR) Position By $17.23 Million; Quinn Opportunity Partners Has Lowered General Motors Co (GM) Position

April 21, 2018 - By Peter Erickson

General Motors Company (NYSE:GM) Logo

Quinn Opportunity Partners Llc decreased General Motors Co (GM) stake by 21.27% reported in 2017Q4 SEC filing. Quinn Opportunity Partners Llc sold 144,500 shares as General Motors Co (GM)’s stock declined 17.02%. The Quinn Opportunity Partners Llc holds 535,000 shares with $21.93 million value, down from 679,500 last quarter. General Motors Co now has $52.67 billion valuation. The stock decreased 0.42% or $0.16 during the last trading session, reaching $37.61. About 8.70M shares traded. General Motors Company (NYSE:GM) has risen 0.46% since April 21, 2017 and is uptrending. It has underperformed by 11.09% the S&P500.

Bb Biotech Ag increased Esperion Therapeutics Inc. (ESPR) stake by 12.63% reported in 2017Q4 SEC filing. Bb Biotech Ag acquired 265,000 shares as Esperion Therapeutics Inc. (ESPR)’s stock rose 22.41%. The Bb Biotech Ag holds 2.36 million shares with $155.58M value, up from 2.10 million last quarter. Esperion Therapeutics Inc. now has $1.95B valuation. The stock decreased 0.63% or $0.47 during the last trading session, reaching $73.69. About 203,041 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 89.86% since April 21, 2017 and is uptrending. It has outperformed by 78.31% the S&P500.

Investors sentiment increased to 0.9 in Q4 2017. Its up 0.03, from 0.87 in 2017Q3. It increased, as 64 investors sold GM shares while 322 reduced holdings. 122 funds opened positions while 225 raised stakes. 999.45 million shares or 1.00% less from 1.01 billion shares in 2017Q3 were reported. Bancorporation Of Mellon holds 11.02 million shares. Aqr Cap Mngmt Limited Liability Company reported 11.45M shares. Moreover, Ellington Mgmt Gp Ltd has 0.16% invested in General Motors Company (NYSE:GM) for 24,348 shares. 47 are held by America First Investment Lc. Asset Ltd Liability invested in 5.9% or 171,754 shares. Hamel Associates Inc owns 31,385 shares for 0.61% of their portfolio. 5.91M were accumulated by Clearbridge Ltd Llc. E&G Advsrs Lp invested 0.65% in General Motors Company (NYSE:GM). Farmers Merchants Invests Incorporated has 0% invested in General Motors Company (NYSE:GM). Two Sigma Llc holds 0.01% of its portfolio in General Motors Company (NYSE:GM) for 6,555 shares. Vident Inv Advisory Ltd Liability Corp has invested 0.17% in General Motors Company (NYSE:GM). Milestone Group Inc owns 0.04% invested in General Motors Company (NYSE:GM) for 6,579 shares. Neuberger Berman Group Ltd Liability reported 0.04% of its portfolio in General Motors Company (NYSE:GM). Peoples Financial has 0% invested in General Motors Company (NYSE:GM) for 100 shares. Renaissance holds 5.31 million shares.

Quinn Opportunity Partners Llc increased Time Warner Inc (NYSE:TWX) stake by 548,300 shares to 1.24 million valued at $113.58 million in 2017Q4. It also upped China Mobile Ltd (NYSE:CHL) stake by 67,600 shares and now owns 114,000 shares. Allergan Plc was raised too.

Analysts await General Motors Company (NYSE:GM) to report earnings on April, 26 before the open. They expect $1.26 earnings per share, down 25.88% or $0.44 from last year’s $1.7 per share. GM’s profit will be $1.76 billion for 7.46 P/E if the $1.26 EPS becomes a reality. After $1.65 actual earnings per share reported by General Motors Company for the previous quarter, Wall Street now forecasts -23.64% negative EPS growth.

Among 29 analysts covering General Motors Company (NYSE:GM), 17 have Buy rating, 3 Sell and 9 Hold. Therefore 59% are positive. General Motors Company had 94 analyst reports since July 24, 2015 according to SRatingsIntel. RBC Capital Markets maintained the stock with “Hold” rating in Tuesday, July 25 report. As per Monday, January 25, the company rating was maintained by Barclays Capital. On Monday, October 2 the stock rating was maintained by Citigroup with “Buy”. The rating was upgraded by Citigroup on Wednesday, October 25 to “Buy”. The stock has “Hold” rating by Wolfe Research on Tuesday, June 13. The stock of General Motors Company (NYSE:GM) earned “Strong-Buy” rating by Tigress Financial on Friday, March 31. Credit Suisse upgraded General Motors Company (NYSE:GM) rating on Friday, July 24. Credit Suisse has “Neutral” rating and $33 target. Barclays Capital maintained the shares of GM in report on Monday, September 21 with “Hold” rating. The firm earned “Buy” rating on Friday, October 2 by UBS. The stock of General Motors Company (NYSE:GM) earned “Hold” rating by Deutsche Bank on Wednesday, October 14.

Investors sentiment decreased to 1.33 in Q4 2017. Its down 0.34, from 1.67 in 2017Q3. It dropped, as 19 investors sold ESPR shares while 39 reduced holdings. 33 funds opened positions while 44 raised stakes. 22.69 million shares or 0.18% less from 22.73 million shares in 2017Q3 were reported. Ghost Tree Capital Limited Liability Corporation stated it has 3.55% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Gam Holdings Ag, Switzerland-based fund reported 225,000 shares. Bamco has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Rothschild Asset Mngmt Incorporated holds 0.01% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 20,871 shares. Blackrock owns 1.51 million shares or 0% of their US portfolio. Schwab Charles Inv Management owns 90,971 shares for 0% of their portfolio. Hall Laurie J Trustee reported 190 shares stake. Sg Americas Secs Limited Company has 0% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Bailard owns 75,300 shares or 0.31% of their US portfolio. Vanguard Group holds 930,481 shares or 0% of its portfolio. Employees Retirement Of Ohio holds 0.01% or 29,555 shares in its portfolio. The New York-based Tower Llc (Trc) has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Bb Biotech Ag holds 4.38% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 2.36M shares. Credit Suisse Ag reported 1.02 million shares. Caisse De Depot Et Placement Du Quebec has 250,000 shares for 0.04% of their portfolio.

Among 18 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 10 have Buy rating, 0 Sell and 8 Hold. Therefore 56% are positive. Esperion Therapeutics had 62 analyst reports since July 28, 2015 according to SRatingsIntel. Citigroup maintained Esperion Therapeutics, Inc. (NASDAQ:ESPR) rating on Wednesday, June 29. Citigroup has “Buy” rating and $22 target. Jefferies maintained the shares of ESPR in report on Monday, March 19 with “Buy” rating. Needham maintained Esperion Therapeutics, Inc. (NASDAQ:ESPR) rating on Monday, March 20. Needham has “Strong Buy” rating and $58 target. As per Wednesday, August 9, the company rating was maintained by Deutsche Bank. The stock has “Outperform” rating by RBC Capital Markets on Friday, November 6. The firm earned “Buy” rating on Wednesday, October 18 by Needham. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) has “Buy” rating given on Thursday, February 25 by Stifel Nicolaus. The stock has “Outperform” rating by RBC Capital Markets on Tuesday, December 15. The firm earned “Buy” rating on Wednesday, October 18 by Cowen & Co. Chardan Capital Markets maintained it with “Neutral” rating and $100 target in Tuesday, March 27 report.

General Motors Company (NYSE:GM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: